2-氧代-2,3-二羟基噁唑-4-羧酸乙酯 | 874827-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氧代-2,3-二羟基噁唑-4-羧酸乙酯
• 中文别名: 2-氧代-2,3-二氢恶唑-4-羧酸乙酯
• 英文名称: ethyl 2-oxo-2,3-dihydrooxazole-4-carboxylate
• 英文别名: ethyl 2-oxo-3H-1,3-oxazole-4-carboxylate
• CAS: 874827-32-4
• 化学式: C₆H₇NO₄
• 分子量: 157.126
• InChiKey: QWJPLUWNLLBZCY-UHFFFAOYSA-N

物化性质

• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 储存条件：
  存储条件：2-8°C，密封，干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 2-oxo-2,3-dihydrooxazole-4-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 2-oxo-2,3-dihydrooxazole-4-carboxylate
CAS number: 874827-32-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7NO4
Molecular weight: 157.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氧代-2,3-二羟基噁唑-4-羧酸乙酯 在 二异丁基氢化铝 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 0.5h， 以13%的产率得到4-羟甲基恶唑烷-2-酮
  参考文献：
  名称：

  Synthesis of 2-Oxazolone-4-carboxylates from 3-Nosyloxy- and 3-Bromo-2-ketoesters

  摘要：

  New methods for the synthesis of 2-oxazolone-4-carboxylates from 3-nosyloxy- and 3-bromo-2-ketoesters are described. Condensation of 3-nosyloxy-2-ketoesters with methyl carbamate in refluxing toluene in the presence of p-TSA provided 2-oxazolone-4-carboxylates in good yields (41-80%). Alternatively, bromination of alpha-ketoesters with CuBr2 provided 3-bromo-2-ketoesters which condensed with methyl carbamate in the presence of p-TSA and AgOTf under similar conditions to provide 2-oxazolone-4-carboxylates in comparable yields (30-79%). The 2-oxazolone-4-carboxylates bear functionality that can be elaborated to a variety of potentially useful compounds. For example, some of these heterocycles were readily N-acylated, reduced to alcohols, or saponified and coupled with amino acids.

  DOI：

  10.1021/jo010630z
• 作为产物：
  描述：

  Ethoxycarbonyloxazole pyridinium tetrafluoroborate 在 乙酰氧肟酸 、 potassium carbonate 、 均三甲苯 作用下， 以 乙醇 为溶剂， 反应 1.17h， 生成 2-氧代-2,3-二羟基噁唑-4-羧酸乙酯
  参考文献：
  名称：

  氨基杂环和缺电子苯胺的仿生脱氨羟基化

  摘要：

  在此，我们报告了一种用户友好、可扩展且安全的程序，使用四氟硼酸吡啶盐和异羟肟酸将氨基杂环化合物转化为其羟基化类似物。该协议的特点是具有广泛的官能团耐受性，允许对生物相关分子进行选择性修饰。机械实验允许识别整个转化过程中涉及的关键中间体。

  DOI：

  10.1002/anie.202212219

文献信息

• Autotaxin inhibitors
  申请人：Legrand Darren Mark

  公开号：US20140171403A1

  公开（公告）日：2014-06-19

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及一种新型化合物，它们是自体磷脂酶A抑制剂，以及它们的制备方法、含有它们的药物组合物和药物，以及它们在由自体磷脂酶A介导的疾病和紊乱中的应用。
• NEPRILYSIN INHIBITORS
  申请人：Fleury Melissa

  公开号：US20140045906A1

  公开（公告）日：2014-02-13

  In one aspect, the invention relates to compounds having the formula: where X, R a , R b , R 2 , and R 7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下结构的化合物： 其中X、Ra、Rb、R2和R7如规范中定义，或其药学上可接受的盐。这些化合物是具有脑利尿肽酶抑制活性的前药。在另一个方面，该发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Total Synthesis and Biological Activity of Neopeltolide and Analogues
  作者：Viktor V. Vintonyak、Brigitte Kunze、Florenz Sasse、Martin E. Maier

  DOI：10.1002/chem.200801398

  日期：2008.12.8

  compound 50 was prepared. This led to 11-epi-neopeltolide 51. The 5-epimer of neopeltolide, compound 52, could be obtained from the minor isomer of the Prins cyclization. Furthermore, a range of analogues with modifications in the side chain were prepared. All derivatives were checked for toxicity effects on mammalian cell cultures and inhibitory effects on NADH oxidation in submitochondrial particles

  通过Mitsunobu反应将新去内酯的内酯16a的核心结构与含恶唑的侧链23结合，从而提供了具有细胞毒性的天然产物新去内酯（2）。侧链23由恶唑酮24经相应的三氟甲磺酸酯制备。制备23种化合物的关键步骤是Sonogashira偶联，烯胺烷基化和Still-Gennari Horner-Emmons反应。通过在烯丙基化步骤中改变Leighton试剂，制备了内酯16a的11-表位化合物50。这产生了11-表-新邻苯二酚51。新邻苯二酚的5-末端化合物52可以从Prins环化的次要异构体获得。此外，制备了一系列在侧链上具有修饰的类似物。检查所有衍生物对哺乳动物细胞培养物的毒性作用以及对牛心脏线粒体颗粒中NADH氧化的抑制作用。内酯部分的修饰在一定程度上是可以容忍的。另一方面，缩短恶唑与内酯之间的距离会导致活性显着下降。具有额外双键的类似物65与新去内酯本身具有相同或什至更高的活性。
• Neprilysin inhibitors
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US10189823B2

  公开（公告）日：2019-01-29

  In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  一方面，本发明涉及具有以下式子的化合物： 其中 X、Ra、Rb、R2 和 R7 如说明书中所定义，或其药学上可接受的盐。这些化合物是具有肾酶抑制活性的化合物的原药。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的工艺和中间体。
• Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors
  作者：Upendra Argikar、Markus Blatter、Dallas Bednarczyk、Zhuoliang Chen、Young Shin Cho、Michaël Doré、Jennifer L. Dumouchel、Samuel Ho、Klemens Hoegenauer、Toshio Kawanami、Simon Mathieu、Erik Meredith、Henrik Möbitz、Stephen K. Murphy、Saravanan Parthasarathy、Carole Pissot Soldermann、Jobette Santos、Serena Silver、Suzanne Skolnik、Aleksandar Stojanovic

  DOI：10.1021/acs.jmedchem.2c01068

  日期：2022.9.22